Produktbild: Immunotherapy of Cancer

Immunotherapy of Cancer An Innovative Treatment Comes of Age

Fr. 192.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

07.04.2018

Abbildungen

IX, 46 illus., 38 illus. in color., farbige Illustrationen, schwarz-weiss Illustrationen

Herausgeber

Yoshiyuki Yamaguchi

Verlag

Springer Tokyo

Seitenzahl

358

Maße (L/B/H)

23.5/15.5/1.9 cm

Gewicht

624 g

Auflage

Softcover Reprint of the Original 1st 2016 edition

Sprache

Englisch

ISBN

978-4-431-56639-7

Beschreibung

Rezension

“This book covers the history, current status and future of cancer immunotherapy. … The content of the book is simply exiting, well written and fully covering the problem. I strongly recommend this book to everybody working in the field.” (Jan Lakota, Neoplasma, Vol. 64 (1), 2017)

Portrait

Dr. Yoshiyuki Yamaguchi, MD, PhD, Professor, Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan  

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

07.04.2018

Abbildungen

IX, 46 illus., 38 illus. in color., farbige Illustrationen, schwarz-weiss Illustrationen

Herausgeber

Yoshiyuki Yamaguchi

Verlag

Springer Tokyo

Seitenzahl

358

Maße (L/B/H)

23.5/15.5/1.9 cm

Gewicht

624 g

Auflage

Softcover Reprint of the Original 1st 2016 edition

Sprache

Englisch

ISBN

978-4-431-56639-7

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Immunotherapy of Cancer
  • Part I Overview, History, Classification.- Chapter 1 Overview of Current Cancer Immunotherapy.- Part II BRMs and Crude Agents.- Chapter 2 Bacterial Preparations.- Chapter 3 Polysaccharides.- Chapter 4 BCG.- Part III Cytokines.- Chapter 5 αβ-T Cells.- Chapter 6 NKT Cell-Based Immunotherapy.- Chapter 7 Natural Killer Cells.- Chapter 8 γδ T Cell-Based Cancer Immunotherapy.- Chapter 9 Genetically engineered T cells.- Part IV Vaccine Therapy.- Chapter 10 Peptide Vaccine.- Chapter 11 Personalized Peptide Vaccine.- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies.- Chapter 13 Protein vaccine.- Chapter 14 Dendritic Cell-Based Vaccine for Cancer.- Part V Immunoadjuvants.- Chapter 15 CpG Motif.- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy.- Chapter 17 Novel Adjuvants.- Part VI Immunocheckpoints.- Chapter 18 Anti-CTLA-4 Ab.- Chapter 19 Anti-PD-1, PD-L1 Ab.- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals.- Part VII Regulation of Immunosuppression.- Chapter 21 Regulatory T Cells.- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells.- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials.- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials.- Part IX Personalized Immunotherapy.- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.